

Cytomegalovirus Infection Treatment Market, 2012-2023

<https://marketpublishers.com/r/C6360263004EN.html>

Date: January 2018

Pages: 216

Price: US\$ 4,400.00 (Single User License)

ID: C6360263004EN

Abstracts

Global Cytomegalovirus Infection Treatment Market

Cytomegalovirus (CMV) infection is the common herpes virus infection having different symptoms which occurs in all ages of people around the world. Cytomegalovirus (CMV) infection is a communicable and easily prone through the body fluids like urine, saliva, blood, breast milk and semen. The infection may spread fast from urine or saliva from people who are infected with CMV having virus in their bodily fluids. The disease can transmit from pregnant to baby during delivery. Organ transplant and Blood transfusion are the other way for the transmission of the disease.

Cytomegalovirus infection treatment market is mainly propelling by the rise in the prevalence of CMV infections, growing awareness about herpes disease, pipeline drugs which are promising by key market players for the treatment of CMV infection. Moreover, rise in the support of government, and development of healthcare infrastructure are anticipated to fuel the growth of CMV infection treatment market. However, recent expiries of patented drugs, generic drugs that are available for the treatment like Ganciclovir & Foscarnet are anticipated to hamper the market growth of cytomegalovirus infection treatment.

The global cytomegalovirus infection market is classified on the basis of drug class, infection, distribution channel, and geography.

Based on drug class, the global cytomegalovirus infection market is segmented into the following:

Antiviral drugs

Foscarnet

Cytovene

Vistide

Others

Based on infection, the global cytomegalovirus infection market is segmented into the following

Retinitis

Pneumonia

Gastroenteritis

Others (Mouth Ulcers, Pharyngitis, etc.)

Based on distribution channel, the global cytomegalovirus infection market is segmented into the following:

Hospital Pharmacies

Retail Pharmacies

Others

Global cytomegalovirus infection treatment market is anticipated to show effective growth rate in foresee period. Players in the market are heavily investing in R&D for the development of novel therapies and drugs to treat cytomegalovirus infection. Moreover, regulatory bodies of the healthcare sector are having more attention on novel drugs by giving faster approvals and special status for the drugs. For instance, Merck & Co. Inc., developed Letemovir, antiviral drug for the treatment of CMV infection. The drug has received fast track status by the U.S. FDA and the orphan drug status by European

Medicines Agency.

On the basis of Geographical regions, CMV infection treatment market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. North America & Europe were anticipated to contribute major share in the cytomegalovirus infection treatment market due to the high prevalence rate of cytomegalovirus infection. As per Centre for Disease Control and Prevention (CDC), approximately, 80,000 cases of CMV infections were diagnosed in U.S. and Europe. Increased prevalence of cytomegalovirus (CMV) infection in the developing countries and in the areas of lower economic status. Asia-Pacific is anticipated to grow rapidly owing to the large patient pool, and rise in prevalence of many infectious diseases as well as rise in the awareness on cytomegalovirus infections.

Some of the players in cytomegalovirus infection market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.), AiCuris Anti-infective Cures GmbH (Germany) Vical, Inc. (U.S.), Chimerix, Inc. (U.S.) and ViroPharma (U.S.), to name a few

In Feb 2017, Merck & Co., Inc. started pivotal Phase 3 clinical study of letermovir, an antiviral investigational drug for treating clinically significant cytomegalovirus Infectio

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET INTRODUCTION

2.1. Global Cytomegalovirus Infection Treatment Market – Taxonomy

2.2. Global Cytomegalovirus Infection Treatment Market –Definitions

2.2.1. Drug Type

2.2.2. Distribution Channel

3. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Cytomegalovirus Infection Treatment Market Dynamic Factors - Impact Analysis

4. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

5.1. Foscarnet

5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Cytovene

5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Vistide

- 5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.3.3. Market Opportunity Analysis

5.4. Others

- 5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.4.3. Market Opportunity Analysis

6. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET, BY INFECTION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

6.1. Retinitis

- 6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.1.3. Market Opportunity Analysis

6.2. Pneumonia

- 6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.2.3. Market Opportunity Analysis

6.3. Gastroenteritis

- 6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.3.3. Market Opportunity Analysis

6.4. Others (Mouth Ulcers, Pharyngitis, etc.)

- 6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.4.3. Market Opportunity Analysis

7. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

7.1. Hospital Pharmacies

- 7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

- 7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

8. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

8.1. North America

8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

8.6. Global Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

9.1. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1. Antiviral drugs

9.1.1.1. Foscarnet

9.1.1.2. Cytovene

9.1.1.3. Vistide

9.1.1.4. Others

9.2. Infection Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.2.1. Retinitis

9.2.2. Pneumonia

9.2.3. Gastroenteritis

9.2.4. Others (Mouth Ulcers, Pharyngitis, etc.)

9.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2017 – 2023

9.6. North America Cytomegalovirus Infection Treatment Market Dynamics – Trends

10. EUROPE CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

10.1. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Antiviral drugs

10.1.1.1. Foscarnet

10.1.1.2. Cytovene

10.1.1.3. Vistide

10.1.1.4. Others

10.2. Infection Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.2.1. Retinitis

10.2.2. Pneumonia

10.2.3. Gastroenteritis

10.2.4. Others (Mouth Ulcers, Pharyngitis, etc.)

10.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacies

10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

10.5. Europe Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2017 – 2023

10.6. Europe Cytomegalovirus Infection Treatment Market Dynamics – Trends

11. ASIA-PACIFIC CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

11.1. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Antiviral drugs

11.1.1.1. Foscarnet

11.1.1.2. Cytovene

11.1.1.3. Vistide

11.1.1.4. Others

11.2. Infection Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.2.1. Retinitis

11.2.2. Pneumonia

11.2.3. Gastroenteritis

11.2.4. Others (Mouth Ulcers, Pharyngitis, etc.)

11.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.3.1. Hospital Pharmacies

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacies

11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2017 – 2023

11.6. Asia-Pacific Cytomegalovirus Infection Treatment Market Dynamics – Trends

12. LATIN AMERICA CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

12.1. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. Antiviral drugs

12.1.1.1. Foscarnet

12.1.1.2. Cytovene

12.1.1.3. Vistide

12.1.1.4. Others

12.2. Infection Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.2.1. Retinitis

12.2.2. Pneumonia

12.2.3. Gastroenteritis

12.2.4. Others (Mouth Ulcers, Pharyngitis, etc.)

12.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacies

12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2017 – 2023

12.6. Latin America Cytomegalovirus Infection Treatment Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

13.1. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. Antiviral drugs

13.1.1.1. Foscarnet

13.1.1.2. Cytovene

13.1.1.3. Vistide

13.1.1.4. Others

13.2. Infection Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.2.1. Retinitis

13.2.2. Pneumonia

13.2.3. Gastroenteritis

13.2.4. Others (Mouth Ulcers, Pharyngitis, etc.)

13.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.3.1. Hospital Pharmacies

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacies

13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. Gulf Cooperation Council (GCC) Countries

13.4.2. Israel

13.4.3. South Africa

13.4.4. Rest of MEA

13.5. MEA Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2017 – 2023

13.6. MEA Cytomegalovirus Infection Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. F. Hoffmann-La Roche AG (Switzerland)

14.2.2. GlaxoSmithKline plc (U.K.)

14.2.3. Merck & Co., Inc. (U.S.)

14.2.4. AiCuris Anti-infective Cures GmbH (Germany)

14.2.5. Vical, Inc. (U.S.)

14.2.6. Chimerix, Inc. (U.S.)

14.2.7. ViroPharma (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Cytomegalovirus Infection Treatment Market, 2012-2023

Product link: <https://marketpublishers.com/r/C6360263004EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6360263004EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970